Financial Architects (New Jersey)’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-6,460
| Closed | -$352K | – | 111 |
|
|
2022
Q1 | $352K | Sell |
6,460
-476
| -7% | -$25.9K | 0.05% | 238 |
|
|
2021
Q4 | $382K | Buy |
6,936
+5
| +0.1% | +$260 | 0.05% | 239 |
|
|
2021
Q3 | $331K | Buy |
6,931
+3
| +0% | +$151 | 0.05% | 250 |
|
|
2021
Q2 | $345K | Buy |
6,928
+4
| +0.1% | +$192 | 0.05% | 244 |
|
|
2021
Q1 | $309K | Sell |
6,924
-136
| -2% | -$6.17K | 0.05% | 252 |
|
|
2020
Q4 | $325K | Buy |
7,060
+242
| +4% | +$11.1K | 0.06% | 215 |
|
|
2020
Q3 | $321K | Buy |
6,818
+4
| +0.1% | +$200 | 0.07% | 191 |
|
|
2020
Q2 | $347K | Sell |
6,814
-120
| -2% | -$6.16K | 0.08% | 170 |
|
|
2020
Q1 | $328K | Buy |
6,934
+327
| +5% | +$17.4K | 0.09% | 160 |
|
|
2019
Q4 | $388K | Buy |
6,607
+182
| +3% | +$10.1K | 0.08% | 168 |
|
|
2019
Q3 | $343K | Buy |
6,425
+83
| +1% | +$4.27K | 0.08% | 175 |
|
|
2019
Q2 | $317K | Sell |
6,342
-218
| -3% | -$10.9K | 0.06% | 197 |
|
|
2019
Q1 | $343K | Sell |
6,560
-1,446
| -18% | -$72.3K | 0.06% | 216 |
|
|
2018
Q4 | $382K | Sell |
8,006
-1,208
| -13% | -$59.5K | 0.07% | 180 |
|
|
2018
Q3 | $463K | Sell |
9,214
-321
| -3% | -$16.3K | 0.08% | 186 |
|
|
2018
Q2 | $481K | Sell |
9,535
-482
| -5% | -$24.3K | 0.09% | 166 |
|
|
2018
Q1 | $489K | Buy |
10,017
+2,579
| +35% | +$120K | 0.1% | 163 |
|
|
2017
Q4 | $330K | Sell |
7,438
-2,107
| -22% | -$97.3K | 0.06% | 230 |
|
|
2017
Q3 | $485K | Sell |
9,545
-8
| -0.1% | -$406 | 0.09% | 165 |
|
|
2017
Q2 | $515K | Sell |
9,553
-314
| -3% | -$16.7K | 0.09% | 148 |
|
|
2017
Q1 | $520K | Buy |
9,867
+393
| +4% | +$19.9K | 0.09% | 153 |
|
|
2016
Q4 | $456K | Sell |
9,474
-576
| -6% | -$28.5K | 0.11% | 151 |
|
|
2016
Q3 | $541K | Buy |
10,050
+970
| +11% | +$53.2K | 0.15% | 126 |
|
|
2016
Q2 | $492K | Buy |
9,080
+1,770
| +24% | +$93.2K | 0.14% | 130 |
|
|
2016
Q1 | $371K | Sell |
7,310
-1,336
| -15% | -$66.5K | 0.13% | 125 |
|
|
2015
Q4 | $424K | Buy |
8,646
+1,314
| +18% | +$67K | 0.17% | 126 |
|
|
2015
Q3 | $352K | Buy |
7,332
+1,260
| +21% | +$65.6K | 0.15% | 136 |
|
|
2015
Q2 | $316K | Buy |
+6,072
| New | +$342K | 0.11% | 138 |
|
|
2015
Q1 | – | Sell |
-2,358
| Closed | -$126K | – | 973 |
|
|
2014
Q4 | $126K | Buy |
2,358
+1,062
| +82% | +$59.4K | 0.06% | 222 |
|
|
2014
Q3 | $74K | Sell |
1,296
-246
| -16% | -$15.1K | 0.04% | 266 |
|
|
2014
Q2 | $103K | Buy |
+1,542
| New | +$104K | 0.05% | 221 |
|
|
2013
Q4 | – | Sell |
-1,136
| Closed | -$73K | – | 322 |
|
|
2013
Q3 | $73K | Buy |
1,136
+217
| +24% | +$14K | 0.05% | 215 |
|
|
2013
Q2 | $58K | Buy |
+919
| New | +$58.3K | 0.04% | 227 |
|
Other funds holding GSK
JEST
Financial Architects (New Jersey)'s GSK Position: Q2 2022 in Review
Financial Architects (New Jersey) sold out of GSK (GSK) in Q2 2022, closing a stake of 6,460 shares — an estimated $352K sold.
Financial Architects (New Jersey) first reported a position in GSK in Q2 2013 and held it in 33 quarters. The position peaked at $541K in Q3 2016. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.
- Financial Architects (New Jersey) reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
- Financial Architects (New Jersey) sold 6,460 GSK shares in Q2 2022, an estimated $352K.
- Financial Architects (New Jersey) first reported a position in GSK in Q2 2013 and held it in 33 quarters.
- Financial Architects (New Jersey)'s GSK position peaked at $541K in Q3 2016.
- 900 funds tracked by Wall St. Rank held GSK as of Q2 2022.
Based on Financial Architects (New Jersey)'s 13F filing for Q2 2022, filed 11 Aug 2022.